TGFB1 and systemic sclerosis: Inhibition of IRE1α, using the inhibitor 4μ8C, was found to inhibit TGFβ‐induced activation of myofibroblasts in vitro, reduced liver and skin fibrosis in vivo, and reverted the profibrotic phenotype of activated myofibroblasts isolated from patients with systemic sclerosis.